| Name | Title | Contact Details |
|---|
People come to Murad when they`re ready to transform the life of their skin. Murad guarantees that transformation because only Murad combines advanced scientific research and practical clinical experience to create high performance skincare products, dietary supplements and lifestyle programs that help people look and feel their absolute best. As America`s first authentic doctor-developed brand, Murad remains true to the scientific principles of its founder, world-renowned dermatologist Howard Murad, M.D. Shaped by his Inclusive Health philosophy and inspired by the real problems of the more than 50,000 patients and clients who have visited his Los Angeles dermatology practice and Inclusive Health Spa®, his award-winning formulas have helped millions to resolve their skin issues. Through more than fifty years of research, Dr. Murad has established that beauty and health are vitally linked and best achieved through an Inclusive approach that improves every cell in the body. The result? The Murad Glow!
Phil is a B2B2C platform that connects patients, pharmacies, prescribers, and manufacturers in the specialty prescription ecosystem. We build software solutions & end-to-end services to power the $320B industry.
Apollo MarCom is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Onward Healthcare is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.